Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LHCGR | P22888 | 11/20 | 0.64 |
| ▸ | FSHR | P23945 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5026884 | 1.00 | LHCGR (0.64) | LHCGRFSHRTSHRMAP4K4JAK3 | |
| SCHEMBL30673524 | 0.93 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL5028842 | 0.93 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL5028832 | 0.93 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL30673520 | 0.93 | LHCGR (0.67) | LHCGRFSHRTSHR | |
| SCHEMBL5025963 | 0.93 | LHCGR (0.66) | LHCGRFSHRTSHR | |
| SCHEMBL30673521 | 0.93 | LHCGR (0.66) | LHCGRFSHRTSHR | |
| SCHEMBL30673522 | 0.92 | LHCGR (0.64) | LHCGRFSHRTSHR | |
| SCHEMBL5026093 | 0.92 | LHCGR (0.64) | LHCGRFSHRTSHR | |
| SCHEMBL5025965 | 0.91 | LHCGR (0.64) | LHCGRFSHRTSHRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-23 | — | — | US | claimed |
| CN-119894515-A | Methods of treating obesity with luteinizing hormone receptor agonists | 西奈山伊坎医学院 | 2025-04-25 | — | — | CN | claimed |
| EP-4536352-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | Icahn School of Medicine at Mount Sinai (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | claimed |
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | ICAHN SCHOOL MED MOUNT SINAI (US) | 2025-10-23 | — | — | US | disclosed |
| CN-119894515-A | Methods of treating obesity with luteinizing hormone receptor agonists | 西奈山伊坎医学院 | 2025-04-25 | — | — | CN | disclosed |
| EP-4536352-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | Icahn School of Medicine at Mount Sinai (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239854-A2 | METHOD OF TREATING OBESITY WITH A LUTEINIZING HORMONE RECEPTOR AGONIST | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325555-A1 | Method of Treating Obesity with a Luteinizing Hormone Receptor Agonist | GNRHR, LHCGR, FSHR | LHCGR 2/4885FSHR 3/4885TSHR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.